One of the strongest - and most concerning - studies so far. A true before/after design, a clear tau signal in persistent neurological symptoms, and nearly half exceeding Alzheimer’s research pTau-181 thresholds🧵
Related evidence. A large UK Biobank longitudinal analysis in Nature Medicine - Duff et al., 2025 -compared plasma Alzheimer’s-related biomarkers before vs after SARS-CoV-2 infection (with matched controls).
They found that SARS-CoV-2 infection was associated with a shift toward an AD-like biomarker profile - notably a reduced plasma Aβ42:Aβ40 ratio, and in more vulnerable participants lower Aβ42 and higher pTau-181.
Taken together with the new N-PASC pTau-181 findings, the message is consistent - across different cohorts and designs, SARS-CoV-2 can be followed by measurable changes in biomarkers linked to neurodegenerative pathways.
Lancet eBioMedicine shows a pTau-181 signal in neurological long COVID.
Nature Medicine shows post–SARS-CoV-2 shifts in AD-related biomarkers, including pTau-181, in vulnerable groups.
Different cohorts. Same warning signal.
Ignoring converging tau and amyloid signals reported by Lancet and Nature is not caution - it risks becoming the public health error of the century. @szupraha @ZdravkoOnline @adamvojtech86
Duff at al., Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. nature.com/articles/s4159…
Share this Scrolly Tale with your friends.
A Scrolly Tale is a new way to read Twitter threads with a more visually immersive experience.
Discover more beautiful Scrolly Tales like this.